The pattern recognition module provides an execution environment for Short Line Candle recognition and related indicators on Beam Therapeutics. It emphasizes pattern recognition signals tied to momentum and continuation while keeping volatility, risk, and performance context in view.
The output start index for this execution was ten with a total number of output elements of fifty-one. The function generated a total of six valid pattern recognition events for the selected time horizon. The Short Line Candle pattern describes signals for either bullish or bearish trend during either reversal or continuation condition of Beam Therapeutics.
Beam Therapeutics Technical Analysis Modules
Most technical analysis of Beam Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Beam from various momentum indicators to cycle indicators. When you analyze Beam charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 507 people. The stock overview for Beam Therapeutics summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/E of 37.48, P/B of 2.15, profit margin of -57.24%. Beam Therapeutics has a market cap of 2.66 B, P/E of 37.48, ROE of -8.11%.
Methodology
Unless otherwise specified, financial data for Beam Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Beam (USA Stocks:BEAM) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Beam Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Beam Therapeutics is covered by 17 analysts. 8 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, Jefferies, Goldman Sachs, Evercore ISI, among others. Updates may occur throughout the day.
Tracking Beam Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A structured review of Beam Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Beam Therapeutics Stock. Outlined below are key reports that provide context for Beam Therapeutics Stock:
Beam Therapeutics has a market cap of 2.66 B, operating margin of -15.29%, ROE of -8.11%. Use Trending Equities to explore allocation context. This includes a position in Beam Therapeutics within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Beam Stock refer to our How to Trade Beam Stock guide.Analysis related to Beam Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Earnings Share
-0.81
Revenue Per Share
1.413
Quarterly Revenue Growth
2.795
Return On Assets
-0.19
Return On Equity
-0.08
The market value of Beam Therapeutics is measured differently than book value, which reflects Beam accounting equity. Beam Therapeutics' market capitalization is 2.66 B. A P/B ratio of 2.15 indicates the market values Beam Therapeutics above its accounting book value. Enterprise value stands at 1.57 B. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Beam Therapeutics' intrinsic value and market price are different measures derived from different inputs. For Beam Therapeutics, key inputs include a P/E ratio of 37.48, a P/B ratio of 2.15, a profit margin of -57.24%, and ROE of -8.11%. By contrast, market price reflects the level where buyers and sellers transact.
Ellen Johnson · Member of Macroaxis Editorial Board